Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,471 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation.
Xu H, Van der Jeught K, Zhou Z, Zhang L, Yu T, Sun Y, Li Y, Wan C, So KM, Liu D, Frieden M, Fang Y, Mosley AL, He X, Zhang X, Sandusky GE, Liu Y, Meroueh SO, Zhang C, Wijeratne AB, Huang C, Ji G, Lu X. Xu H, et al. Among authors: yu t. J Clin Invest. 2021 May 17;131(10):e146832. doi: 10.1172/JCI146832. J Clin Invest. 2021. PMID: 33830945 Free PMC article.
ST2 as checkpoint target for colorectal cancer immunotherapy.
Van der Jeught K, Sun Y, Fang Y, Zhou Z, Jiang H, Yu T, Yang J, Kamocka MM, So KM, Li Y, Eyvani H, Sandusky GE, Frieden M, Braun H, Beyaert R, He X, Zhang X, Zhang C, Paczesny S, Lu X. Van der Jeught K, et al. Among authors: yu t. JCI Insight. 2020 May 7;5(9):e136073. doi: 10.1172/jci.insight.136073. JCI Insight. 2020. PMID: 32376804 Free PMC article.
MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation.
Fang Y, Wang L, Wan C, Sun Y, Van der Jeught K, Zhou Z, Dong T, So KM, Yu T, Li Y, Eyvani H, Colter AB, Dong E, Cao S, Wang J, Schneider BP, Sandusky GE, Liu Y, Zhang C, Lu X, Zhang X. Fang Y, et al. Among authors: yu t. J Clin Invest. 2021 Jan 4;131(1):e140837. doi: 10.1172/JCI140837. J Clin Invest. 2021. PMID: 32990678 Free PMC article.
An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity.
Zhou Z, Van der Jeught K, Fang Y, Yu T, Li Y, Ao Z, Liu S, Zhang L, Yang Y, Eyvani H, Cox ML, Wang X, He X, Ji G, Schneider BP, Guo F, Wan J, Zhang X, Lu X. Zhou Z, et al. Among authors: yu t. Nat Biomed Eng. 2021 Nov;5(11):1320-1335. doi: 10.1038/s41551-021-00805-x. Epub 2021 Nov 1. Nat Biomed Eng. 2021. PMID: 34725507 Free PMC article.
A T Cell-Engaging Tumor Organoid Platform for Pancreatic Cancer Immunotherapy.
Zhou Z, Van der Jeught K, Li Y, Sharma S, Yu T, Moulana I, Liu S, Wan J, Territo PR, Opyrchal M, Zhang X, Wan G, Lu X. Zhou Z, et al. Among authors: yu t. Adv Sci (Weinh). 2023 Aug;10(23):e2300548. doi: 10.1002/advs.202300548. Epub 2023 Jun 4. Adv Sci (Weinh). 2023. PMID: 37271874 Free PMC article.
Author Correction: An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity.
Zhou Z, Van der Jeught K, Fang Y, Yu T, Li Y, Ao Z, Liu S, Zhang L, Yang Y, Eyvani H, Cox ML, Wang X, He X, Ji G, Schneider BP, Guo F, Wan J, Zhang X, Lu X. Zhou Z, et al. Among authors: yu t. Nat Biomed Eng. 2023 Aug 30. doi: 10.1038/s41551-023-01096-0. Online ahead of print. Nat Biomed Eng. 2023. PMID: 37648780 No abstract available.
Metabolic collateral lethal target identification reveals MTHFD2 paralogue dependency in ovarian cancer.
Achreja A, Yu T, Mittal A, Choppara S, Animasahun O, Nenwani M, Wuchu F, Meurs N, Mohan A, Jeon JH, Sarangi I, Jayaraman A, Owen S, Kulkarni R, Cusato M, Weinberg F, Kweon HK, Subramanian C, Wicha MS, Merajver SD, Nagrath S, Cho KR, DiFeo A, Lu X, Nagrath D. Achreja A, et al. Among authors: yu t. Nat Metab. 2022 Sep;4(9):1119-1137. doi: 10.1038/s42255-022-00636-3. Epub 2022 Sep 21. Nat Metab. 2022. PMID: 36131208
9,471 results